All In Biotech

Drug Trial Radar · NCT07911735

A Study Evaluating the Efficacy and Safety of SYH2072 Tablets In Hypertensive Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Trial of SYH2072 Tablets for Uncontrolled Hypertension (Including Resistant Hypertension) in Patients on Two or More Antihypertensive Agents

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 264 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

264

Planned (sponsor's estimate)

Start

Dec 13, 2026

Primary completion

Jul 22, 2027

Study completion Nov 28, 2027

Sponsor

Sponsor type
Industry
First posted
Nov 3, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

SYH2072 is a highly selective aldosterone synthase inhibitor. This is a multicenter, randomized, double-blind, placebo-controlled Phase II study designed to evaluate the efficacy and safety of SYH2072 tablets in patients with uncontrolled hypertension (including patients with resistant hypertension) receiving stable treatment with two or more antihypertensive agents.

Conditions

  • Uncontrolled Hypertension
  • Resistant Hypertension

Interventions

  • SYH2072 TabletsDrug

    Low-dose

  • SYH2072 TabletsDrug

    Middle-dose

  • SYH2072 TabletsDrug

    high-dose

  • placeboDrug

    placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in mean seated systolic blood pressure (msSBP)Time frame: at week 12

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.